Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Cf 1743

Known as: Cf-1743, Cf1743 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyrimidine Nucleosides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Pharmacokinetics and Safety of FV-100, a Novel Oral Anti-Herpes Zoster Nucleoside Analogue, Administered in Single and Multiple Doses to Healthy Young Adult and Elderly Adult Volunteers
ABSTRACT FV-100 is the prodrug of the highly potent anti-varicella zoster virus bicyclic nucleoside analogue CF-1743. To… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Review
2010
Review
2010
FV-100: The Most Potent and Selective Anti-Varicella Zoster Virus Agent Reported to Date
  • Marco Migliore
  • Antiviral chemistry & chemotherapy
  • 2010
    • Corpus ID: 19451113
Bicyclic aryl furano pyrimidines represent the most potent anti-varicella zoster virus (VZV) agents reported to date. Lead… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2010
2010
Evaluation of Novel Phosphoramidate ProTides of the 2′-Fluoro Derivatives of a Potent Anti-Varicella Zoster Virus Bicyclic Nucleoside Analogue
Background: Recently, the synthesis and antiviral activity of a series of 2′-fluoro derivatives of the most potent anti-varicella… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2009
Review
2009
FV100 as a new approach for the possible treatment of varicella-zoster virus infection.
FV100 is a promising new agent with extreme potency and specificity for varicella-zoster virus (VZV). It is the valyl ester pro… Expand
  • figure 1
  • figure 2
2009
2009
A Study of the Safety and Pharmacokinetics of Multiple Ascending Doses of FV-100 in Healthy Subjects
Twenty-two of 42 subjects reported at least 1 AEs (Table 2); 23 were thought by the Investigator to be possibly related to study… Expand
Highly Cited
2007
Highly Cited
2007
Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus.
OBJECTIVES To progress the anti-varicella-zoster-virus (VZV) aryl bicyclic nucleoside analogues (BCNAs) to the point of Phase 1… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE